Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Globus Medical, driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.74 per share, reflecting a +2.8% change year-over-year, with revenues projected at $628.32 million, up 3.6% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Globus Medical is higher than the consensus estimate, resulting in a positive Earnings ESP of +2.40%, indicating a bullish sentiment among analysts [10]. Historical Performance - Globus Medical has a strong track record, having beaten consensus EPS estimates in the last four quarters, including a +10.53% surprise in the most recent quarter [12][13]. Stock Ranking - The company currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11]. Conclusion - Globus Medical is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors beyond earnings expectations when making investment decisions [16].

Core Insights - The first-quarter reporting cycle shows a positive trend with most companies exceeding earnings estimates, although macroeconomic uncertainty is affecting future earnings outlooks [1] - The Medical sector is experiencing significant earnings growth, acting as a buffer against rising market volatility due to increasing tariffs [1][2] Medical Sector Performance - Key medical product companies are recovering from previous cost increases and supply-chain disruptions, with artificial intelligence integration expected to drive medical device adoption in 2025 [2] - At-home medical solutions are projected to continue their growth trend in 2025, despite potential negative impacts from rising tariffs [2] - As of April 30, 45% of Medical sector companies reported quarterly earnings, with 85.2% beating earnings estimates and 70.4% exceeding revenue expectations [3] - Year-over-year earnings in the Medical sector improved by 60.5%, while revenues increased by 7.8% [3] Earnings Expectations - The Medical sector's first-quarter earnings are anticipated to surge by 40%, with sales expected to rise by 8.3% year over year [4] - Hims & Hers Health is projected to report a first-quarter EPS of 14 cents, indicating a 180% growth from the previous year [8] - Globus Medical's first-quarter EPS is estimated at 74 cents, reflecting a 2.8% increase from the prior year [10] - QuidelOrtho's first-quarter EPS is expected to be 60 cents, showing a 36.4% improvement from the year-ago period [11] - Haemonetics is anticipated to report a first-quarter EPS of $1.22, suggesting a 35.6% increase from the previous year [12]

Core Viewpoint - Globus Medical, Inc. will announce its financial results for the first quarter ended March 31, 2025, on May 8, 2025, after market close [1] Financial Results Announcement - The financial results will be available on the Globus Medical website [1] - A teleconference will be held at 4:30 p.m. Eastern Time to discuss the performance with the investment community [2] - Participants can access the conference call live via webcast on the Investors page of the Globus Medical website [2] Teleconference Participation - Telephone participants must register in advance to receive a confirmation email with details on how to join the call [3] - The audio archive of the call will be available on the Investors page after the event [3] Company Overview - Globus Medical, Inc. is a leading global musculoskeletal company focused on addressing unmet clinical needs [4] - The company emphasizes innovation, education, clinical support, and advancements in various medical fields including spine, orthopedic trauma, and joint reconstruction [4]

Company Overview - Globus Medical, Inc. (GMED) has completed the acquisition of Nevro Corp., enhancing its position in the musculoskeletal market [1] - The acquisition is expected to unlock a market opportunity valued at $2.50 billion [4] Financial Performance - Globus Medical has a market capitalization of $9.47 billion, with projected revenues for 2025 expected to increase by 6.5% year over year [3] - Following the acquisition, net sales projections for 2025 are estimated to be between $2.80 billion and $2.90 billion, an increase from previous estimates of $2.66 billion to $2.69 billion [6] Market Trends - The global orthopedic devices market was valued at $59.4 billion in 2023, with a projected compound annual growth rate of 5.3% through 2032, driven by factors such as the rising prevalence of osteoporosis and musculoskeletal diseases [7] Recent Developments - Globus Medical recently launched the COHERE ALIF Spacer, a new product designed for anterior lumbar interbody fusion surgery, along with Modulus ALIF Blades, expanding its product offerings [9] Stock Performance - Since the acquisition announcement on April 3, shares of Globus Medical have decreased by 4.6%, closing at $72.02 [2] - Over the past year, GMED shares have increased by 29.5%, contrasting with an 18.8% decline in the industry [10]

AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. "We are excited to begin the journey of accelerating market penetration of Nevro's differentiated high-frequency technology and bringing a much-needed treatment option to ...

Globus Medical, Inc. (GMED) continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global musculoskeletal company focused on rapid innovation, addressing unmet clinical needs, and improving offerings to surgeons and patients. Additionally, its string of product launches is highly promising to drive growth in the coming quarters. Meanwhile, headwinds from adverse macroeconomic events and intense competition rema ...

Core Viewpoint - Globus Medical (GMED) is experiencing growth in demand for its Musculoskeletal Solutions products, but faces challenges from a difficult macroeconomic environment, leading to a current Zacks Rank of 3 (Hold) [1] Factors Driving GMED's Shares - The company is gaining market share in musculoskeletal solutions, driven by strong performance in implantable devices, biologics, accessories, and unique surgical instruments [2] - Notable growth in product categories includes expandables, biologics, minimally invasive surgery (MIS) screws, 3D printed implants, and cervical offerings [2] - In Q4, musculoskeletal sales improved by 4.5% year over year, with a significant contribution from international spine business and a 43.5% increase in global Enabling Technologies revenues [3] - The acquisition of Nevro Corporation is expected to add an additional $2 billion market space to GMED's reach in the musculoskeletal market [3] Product Launches and R&D - In Q4 2024, GMED launched five new products, including the QUARTEX MIS system and the ALLEGIANCE Retractor System, aimed at enhancing surgical procedures [4] - The company anticipates a strong pipeline of product launches in 2025, with R&D expenses projected to increase by 11.2% [5] Business Integration and Synergies - GMED's merger with NuVasive has created a global musculoskeletal company focused on innovation and addressing clinical needs, enhancing customer reach and surgeon relationships [6] - Integration with NuVasive is progressing well, exceeding collaboration targets and accelerating value creation and shareholder returns [7] Market Performance and Competitive Landscape - Over the past three months, GMED shares have declined by 12%, compared to a 3.8% decline in the industry, but the company is expected to regain momentum through strategic market expansion and new product launches [8] - The musculoskeletal devices market is highly competitive, with major players like Zimmer Biomet, Stryker, and Johnson & Johnson's DePuy, necessitating continuous product innovation and acquisitions for GMED to maintain market share [10] Economic Challenges - GMED is facing negative trends in the global economy, including interest rate fluctuations and inflation, which have led to an 88.9% increase in the cost of goods sold and a 52.5% rise in SG&A expenses in 2024 [9]

Core Viewpoint - Globus Medical, Inc. has launched two new products, the COHERE™ ALIF Spacer and Modulus™ ALIF Blades, aimed at enhancing surgical efficiency and patient outcomes in anterior spine surgery [1][3][4] Product Launches - The COHERE™ ALIF Spacer features proprietary porous surface technology that promotes bone in-growth while retaining the imaging and mechanical properties of solid PEEK interbody spacers [1][3] - Modulus™ ALIF Blades provide surgeons with various fixation options using the same interbody spacer, improving procedural efficiency by reducing the number of surgical steps and instruments required [1][2] Clinical Benefits - The integration of Porous PEEK technology in the COHERE™ ALIF Spacer is expected to enhance clinical outcomes for anterior cervical fusion and lumbar spine surgery, with significant benefits in radiographic assessment of fusion [1][3] - The Modulus™ ALIF Blades are designed to minimize complications by reducing instrument passes near major vessels, thus allowing for a more minimally invasive surgical approach [2][3] Commitment to Innovation - Globus Medical emphasizes its dedication to advancing surgical outcomes and providing best-in-class solutions tailored to varying patient anatomies and surgeon preferences [4] - The company aims to address unmet clinical needs through continuous innovation in product development [4][5]

Core Viewpoint - Globus Medical, Inc. has launched two new products, the COHERE™ ALIF Spacer and Modulus™ ALIF Blades, aimed at enhancing surgical outcomes in anterior spine surgery through innovative technology and procedural efficiency [1][3][4]. Product Launches - The COHERE™ ALIF Spacer features proprietary porous surface technology that promotes bone in-growth while retaining the imaging and mechanical properties of solid PEEK interbody spacers [1][3]. - Modulus™ ALIF Blades provide surgeons with various fixation options using the same interbody spacer, improving procedural efficiency by reducing the number of surgical steps and instruments required [1][2]. Clinical Benefits - The integration of Porous PEEK technology is expected to enhance clinical outcomes for anterior cervical fusion and advance patient care in anterior lumbar spine surgery [1][4]. - The low-profile instrumentation and streamlined delivery of fixation with Modulus™ ALIF Blades may reduce complications by minimizing instrument passes near major vessels, thus allowing for a more minimally invasive approach [2][3]. Commitment to Innovation - Globus Medical emphasizes its dedication to advancing surgical outcomes and providing best-in-class solutions tailored to varying patient anatomies and surgeon preferences [4]. - The company aims to address unmet clinical needs through continuous innovation in product development [4][5].

Core Viewpoint - Globus Medical, Inc. will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, showcasing its innovative musculoskeletal technology products and solutions [1][6]. Group 1: Event Participation - The event will take place from March 10-14, 2025, in San Diego, California [1]. - Globus Medical will host a booth (2517) to present its comprehensive product portfolio, including offerings in Spine, Trauma, Joint Reconstruction, Enabling Technology, Power Tools, and Regenerative Biomaterials [2]. Group 2: Featured Technologies - The company will highlight the ExcelsiusFlex™ surgical robotic navigation system for Total Knee Arthroplasty (TKA), designed for accuracy and procedural flexibility [3]. - Other featured products include the PRECICE™ Intramedullary Limb Lengthening Portfolio, DuraPro™ Oscillating System, and Harvest™ SmartPrep™ 3 autologous biologic centrifuge platform [4]. Group 3: Networking Opportunities - Globus Medical will host a reception for attendees to meet the team and learn more about their technology offerings on March 12, 2025, from 5:30 PM to 8:30 PM at the San Diego Wine & Culinary Center [5]. - An investor relations booth tour will also be conducted on March 12, 2025, from 1:00 PM to 1:45 PM, allowing analysts and investors to see the latest innovations [6]. Group 4: Company Overview - Globus Medical, based in Audubon, Pennsylvania, is a leading global musculoskeletal company focused on addressing unmet clinical needs and advancing care in various medical fields [7].